Stock Price
353.57
Daily Change
1.77 0.50%
Monthly
-11.13%
Yearly
27.96%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $131.79M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.28M 241K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Amgen USD 538M 300K Sep/2025
Arrowhead Research USD 135.7M 2.44M Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Incyte USD 196.13M 2.01M Sep/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
Novartis USD 1.92B 17.06M Sep/2025
PTC Therapeutics USD 79.93M 554K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Takeda JPY 1.58B 2K Dec/2025
Tectonic Therapeutic USD 14.86M 111.83K Dec/2024
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025
Xencor USD 71.34M 46K Sep/2025